Effectiveness and safety of Suhuang Zhike capsule (苏黄止咳胶囊) as adjuvant treatment for acute exacerbation of chronic obstructive pulmonary disease: a systematic review and Meta-analysis

doi:10.19852/j.cnki.jtcm.2023.02.004

Abstract

Abstract:

OBJECTIVE: To evaluate the efficacy and safety of Suhuang Zhike capsule (苏黄止咳胶囊) in the adjuvant treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

METHODS: The database including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure Database, China Science and Technology Journal Database, Chinese Biomedical Literature Database and Wanfang Data was searched. The retrieval time was from database establishment to May 2021. Randomized controlled trial (RCT) of Suhuang zhike capsule adjuvant treatment for AECOPD was included. The quality of the studies was independently evaluated and cross-checked by two reviewers, and Meta-analysis was performed by using RevMan5.3 software.

RESULTS: Thirteen RCT results were included with a total sample number of 1195 cases, including 597 in the experimental group and 598 in the control group. The results showed that Suhuang zhike capsule adjuvant treatment of AECOPD could improve the total clinical effect rate compared with conventional treatment. Suhuang zhike capsule adjuvant treatment could improve forced vital capacity (FVC), forced expiratory volume in one second (FEV₁), FEV₁/FVC, peak expiratory flow (PEF) and other pulmonary function indexes; decrease C-reactive protein (CRP), white blood cells, neutrophils and other infectious indicators; besides, the 1-year recurrence rate of the disease was decreased (all P < 0.05).

CONCLUSIONS: Suhuang Zhike capsule can improve the lung function and clinical efficacy of AECOPD, thus increasing the exercise endurance, and reducing the infection and recurrence rate in AECOPD patients.

Key words: pulmonary disease, chronic obstructive, Meta-analysis, acute exacerbation, Suhuang Zhike capsule

DAI Linfeng, ZHUANG Yan, Lü Hai, CHEN Mingqi, WANG Xing. Effectiveness and safety of Suhuang Zhike capsule (苏黄止咳胶囊) as adjuvant treatment for acute exacerbation of chronic obstructive pulmonary disease: a systematic review and Meta-analysis[J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 231-238.

Figures/Tables 5

References 36.

1.	Chen YT, Miao K, Zhou L, Xiong WN. Stem cell therapy for chronic obstructive pulmonary disease. Chin Med J (Engl) 2021; 134: 1535-45.
2.	Hurst JR, Siddiqui MK, Singh B, Varghese P, Holmgren U, de Nigris E. A systematic literature review of the humanistic burden of COPD. Int J Chron Obstruct Pulmon Dis 2021; 16: 1303-14. DOI URL
3.	Barreiro E, Wang X, Tang J. COPD: preclinical models and emerging therapeutic targets. Expert Opin Ther Targets 2019; 23: 829-38. DOI URL
4.	Wang Y, Xu J, Meng Y, Adcock IM, Yao X. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis 2018; 13: 3341-8. DOI URL
5.	Afroz N, Gutzwiller FS, Mackay AJ, Naujoks C, Patalano F, Kostikas K. Patient-Reported Outcomes (PROs) in COPD clinical trials: trends and gaps. Int J Chron Obstruct Pulmon Dis 2020; 15: 1789-1800. DOI URL
6.	Ko FW, Chan KP, Hui DS, et al. Acute exacerbation of COPD. Respirology 2016; 21: 1152-65. DOI PMID
7.	Hogea SP, Tudorache E, Fildan AP, Fira-Mladinescu O, Marc M, Oancea C. Risk factors of chronic obstructive pulmonary disease exacerbations. Clin Respir J 2020; 14: 183-97. DOI URL
8.	Whittaker BS, Braman S. Recent advances in the management of acute exacerbations of chronic obstructive pulmonary disease. Med Clin North Am 2020; 104: 615-30. DOI URL
9.	Duan X, Wu J, Huang X, et al. Comparative efficacy of Chinese herbal injections for treating acute exacerbation of chronic obstructive pulmonary disease: a bayesian network Meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2018; 2018: 7942936.
10.	Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med 2020; 41: 421-38. DOI PMID
11.	Fan Y, Wen X, Zhang Q, et al. Effect of Traditional Chinese Medicine Bufei granule on stable chronic obstructive pulmonary disease: a systematic review and Meta-analysis based on existing evidence. Evid Based Complement Alternat Med 2020; 2020: 3439457.
12.	Yang J. Observation of the effects of the Suhuang Zhike capsule on acute bronchitis. J Biol Regul Homeost Agents 2017; 31: 453-57.
13.	Zhu ML, Zhang FY, Zhang H, et al. Critical quality attribute assessment of big brand Traditional Chinese Medicine: process quality control method of Suhuang Zhike capsules intermediate based on physical properties of powder and granules. Zhong Guo Zhong Yao Za Zhi 2021; 46: 1636-43.
14.	Wang ZH, Zhang MP, Zhang HX, et al. Pharmacoeconomic evaluation of Suhuang Zhike capsules using Markov model for inpatients with acute exacerbation of chronic obstructive pulmonary disease. Zhong Guo Zhong Yao Za Zhi 2021; 46: 2588-93.
15.	Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease:the GOLD science committee report 2019. Eur Respir J 2019; 53-4.
16.	Yang H, Qiu D, Du F. Eliminating phlegm effect of Suhuang Zhike Jiaonang on acute exacerbation of chronic obstructive pulmonary disease. Ji Ceng Yi Xue Lun Tan 2014; 18: 2891-2.
17.	Wang X, Wang X, Wan Y, et al. Clinical evaluation of supportive treatment with Suhuangzhike capsules against acute exacerbation of chronic obstructive pulmonary disease. Zhong Guo Yi Yuan Yao Xue Za Zhi 2016; 36: 937-9.
18.	Huang Y, Sun G, Zhou L, Lu C, Chang S. Observation and analysis of clinical efficacy of Suhuang Zhike capsule for patients with acute exacerbation of chronic obstructive pulmonary disease. Shi Jie Zhong Yi Yao 2017; 12: 2023-7.
19.	Zhou Y, Xu H, Zhou H. Clinical observation of Suhuang Zhike capsule in adjuvant treatment of senile chronic obstructive pulmonary disease in acute exacerbation stage. Zhong Yi Yao Dao Bao 2017; 23: 89-91.
20.	Zhao N, Li Y. Long term follow up study of Suhuang Zhike capsule treatment of patients with chronic obstructive pulmonary disease. Liaoning: Liaoning Zhong Yi Za Zhi 2017; 44: 1235-8.
21.	Li J, Wang D. Clinical observation of Suhuang Zhike capsule in treating acute exacerbation of chronic obstructive pulmonary disease. Yao Wu Ping Jia 2018; 15: 57-8.
22.	Ou C, Zhang W, Li D. Clinical eficacy of the Suhuang Zhike capsule on acute exacerbation of chronic obstructive pulmonary. Zhong Guo Lin Chuang Yan Jiu 2018; 10: 14-6.
23.	Zhang Y, Yao B, Wu Y, Xu Z. Effect of Suhuang Zhike capsule combined with fluticasone propionate and salmeterol in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Lin Chuang Yi Xue Yan Jiu Yu Shi Jian 2018; 3: 20-1.
24.	Wu M. Observation on curative effect of Suhuang Zhike capsule in the acute exacerbation of chronic obstructive pulmonary disease. Hai Xia Yao Xue 2018; 30: 129-31.
25.	Wang Y, Ji M, Song S, Hua R. Clinical study on Suhuang Zhike capsules combined with ambroxol in treatment of acute exacerbation of chronic obstructive pulmonary disease. Xian Dai Yao Wu Yu Lin Chuang 2019; 34: 2381-5.
26.	Ren J. Effect of Suhuang Zhike capsule on pulmonary function, blood gas analysis, serum PCT and CRP in patients with acute exacerbation of chronic obstructive pulmonary disease. Xian Dai Zhong Xi Yi Jie He Za Zhi 2019; 28: 1442-5.
27.	Peng G. Clinical effect of Suhuang Zhike capsule in treating patients with acute exacerbation of chronic obstructive pulmonary disease. Zhong Guo Chu Fang Yao 2019; 17: 140-1.
28.	Chang W. Analysis of the curative effect of Suhuang Zhike capsule in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Heilongjiang: Heilongjiang Zhong Yi Yao 2020; 49: 78-9.
29.	Kenn K, Gloeckl R, Leitl D, et al. Protocol for an observational study to identify potential predictors of an acute exacerbation in patients with chronic obstructive pulmonary disease (the PACE Study). BMJ Open 2021; 11: e43014.
30.	Cai BQ, Cai SX, Chen RC, et al. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People's Republic of China. Int J Chron Obstruct Pulmon Dis 2014; 9: 381-95.
31.	Cong S, Yao JY, Fan J, et al. Analysis on awareness of chronic obstructive pulmonary disease (COPD) status and related knowledge in patients with COPD in China, 2014-2015. Zhong Hua Liu Xing Bing Xue Za Zhi 2020; 41: 1034-40.
32.	Mantero M, Rogliani P, Di Pasquale M, et al. Acute exacerbations of COPD: risk factors for failure and relapse. Int J Chron Obstruct Pulmon Dis 2017; 12: 2687-93. DOI URL
33.	Zhou A, Zhou Z, Zhao Y, Chen P. The recent advances of phenotypes in acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2017; 12: 1009-18. DOI URL
34.	Gu C, Peng W, Wang Z, Xu Y, Han D, Zhou X. Suhuang Zhike capsules for the treatment of cough variant asthma: a Meta-analysis. Evid Based Complement Alternat Med 2020; 2020: 9485746.
35.	Agarwala P, Salzman SH. Six-minute walk test: clinical role, technique, coding, and reimbursement. Chest 2020; 157: 603-11. DOI PMID
36.	Fermont JM, Masconi KL, Jensen MT, et al. Biomarkers and clinical outcomes in COPD: a systematic review and Meta-analysis. Thorax 2019; 74: 439-46. DOI PMID

Study	N (T/C)	Age (T/C) (mean±SD)	Course of Treatment (days)	Interventions		Outcome
Study	N (T/C)	Age (T/C) (mean±SD)	Course of Treatment (days)	T	C	Outcome
Yang HJ et al 2014¹⁶	30/30	61.8±9.2/64.5±8.4	10	SHZK+C	CT	①②
Wang XP et al 2016¹⁷	30/30	65.9±6.2/60.3±4.6	10	SHZK+C	AH+ICS+CT	①⑤
Huang YF et al 2017¹⁸	45/45	67.57±5.25/68.05±5.57	56	SHZK+C	LABA+ICS+CT	②④⑥
Zhou YL et al 2017¹⁹	60/60	68.4±5.6/68.8±6.2	7	SHZK+C	AH+CT	①②③⑤
Zhao NK, Li Y 2017²⁰	53/54	67.57±5.25/68.05±5.57	28	SHZK+C	CT	②④⑥
Li J, Wang D 2018²¹	38/38	60.8±4.4/61.2±4.5	14	SHZK+C	AH+ICS+CT	①⑤
Ou CL et al 2018²²	60/60	65.42±4.68/65.05±4.68	60	SHZK+C	CT	②⑥
Zhang YL et al 2018²³	42/42	64.26±7.42/64.18±7.35	14	SHZK+C	LABA+ICS	①②③
Wu MJ 2018²⁴	30/30	67.3±5.68/60.1±6.14	14	SHZK+C	SAMA+AH+CT	①④⑤
Wang YM et al 2019²⁵	80/80	61.8±5.5/60.9±5.9	10	SHZK+C	AH+CT	①②⑤
Ren JQ 2019²⁶	44/44	75.5±4.3/75.3±4.2	7	SHZK+C	SAMA+AH+SABA+ICS+CT	①②③⑤
Peng GY 2019²⁷	36/36	65.41±5.79/64.29±5.76	30	SHZK+C	LABA+ICS+CT	②⑥
Chang WY 2020²⁸	49/49	65.6±4.7/64.3±4.5	56	SHZK+C	SAMA+ICS+AH+CT	①⑤

Study	N (T/C)	Age (T/C) (mean±SD)	Course of Treatment (days)	Interventions		Outcome
Study	N (T/C)	Age (T/C) (mean±SD)	Course of Treatment (days)	T	C	Outcome
Yang HJ et al 2014¹⁶	30/30	61.8±9.2/64.5±8.4	10	SHZK+C	CT	①②
Wang XP et al 2016¹⁷	30/30	65.9±6.2/60.3±4.6	10	SHZK+C	AH+ICS+CT	①⑤
Huang YF et al 2017¹⁸	45/45	67.57±5.25/68.05±5.57	56	SHZK+C	LABA+ICS+CT	②④⑥
Zhou YL et al 2017¹⁹	60/60	68.4±5.6/68.8±6.2	7	SHZK+C	AH+CT	①②③⑤
Zhao NK, Li Y 2017²⁰	53/54	67.57±5.25/68.05±5.57	28	SHZK+C	CT	②④⑥
Li J, Wang D 2018²¹	38/38	60.8±4.4/61.2±4.5	14	SHZK+C	AH+ICS+CT	①⑤
Ou CL et al 2018²²	60/60	65.42±4.68/65.05±4.68	60	SHZK+C	CT	②⑥
Zhang YL et al 2018²³	42/42	64.26±7.42/64.18±7.35	14	SHZK+C	LABA+ICS	①②③
Wu MJ 2018²⁴	30/30	67.3±5.68/60.1±6.14	14	SHZK+C	SAMA+AH+CT	①④⑤
Wang YM et al 2019²⁵	80/80	61.8±5.5/60.9±5.9	10	SHZK+C	AH+CT	①②⑤
Ren JQ 2019²⁶	44/44	75.5±4.3/75.3±4.2	7	SHZK+C	SAMA+AH+SABA+ICS+CT	①②③⑤
Peng GY 2019²⁷	36/36	65.41±5.79/64.29±5.76	30	SHZK+C	LABA+ICS+CT	②⑥
Chang WY 2020²⁸	49/49	65.6±4.7/64.3±4.5	56	SHZK+C	SAMA+ICS+AH+CT	①⑤

[1]	QIN Xiaoyu, WANG Chunai, XUE Jianjun, ZHANG Jie, LU Xiaoting, DING Shengshuang, GE Long, WANG Minzhen. Efficacy of electroacupuncture on myocardial protection and postoperative rehabilitation in patients undergoing cardiac surgery with cardiopulmonary bypass: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 1-15.
[2]	LIU Tingting, LIU Tongou, LIU Mingfu. Effectiveness and safety of acupuncture in treatment of pregnancy-related symptoms: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 16-26.
[3]	WANG Jiabao, ZHANG Lishuang, NIU Baihan, YU Yajun, YANG Fengwen, MIAO Lin, CHAI Lijuan, DING Xinya, SUN Yingjie, WANG Yujing, WANG Lin, ZHANG Han, WANG Yi, LI Lin. Efficacy and safety of Weichang’ an pill (胃肠安丸) combined with Western Medicine on gastrointestinal diseases: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1057-1067.
[4]	FAN Rong, HE Haoyu, TANG Tao, CUI Hanjin. Long-term effects of Qingfei Paidu decoction (清肺排毒汤) in patients with coronavirus disease 2019 acute pneumonia after treatment: a protocol for systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1068-1071.
[5]	YANG Yuqing, CHEN Yuhuan, LI Chunxiao, LING Xiao, WANG Panpan, GUO Jing, ZHANG Yingying. Effectiveness and safety of Pingxiao capsule (平消胶囊) as adjuvant therapy in treatment of breast cancer: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 851-859.
[6]	ZHAO HuiYan, JUN Purumea, LEE Chaewon, HAN Chang-Hyun. Acupoint catgut embedding for simple obesity in animal studies: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 860-867.
[7]	SUN Wu, ZHAO Yuwei, LIAO Liang, ZHAO Zhonghui, CHEN Shiqi, YAN Xiaoling, WANG Xueyao, CHAO Guojun, ZHOU Jian. Effectiveness and safety of Xuebijing injection for patients with coronavirus disease 2019: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 631-639.
[8]	WANG Chao, WU Qiong, LI Ping, WANG Zhigang, LOU Xusheng, LI Yuanyuan, ZHANG Lin. Effect of Traditional Chinese Medicine combined with Western Medicine on blood lipid levels and inflammatory factors in patients with angina pectoris in coronary heart disease identified as intermingled phlegm and blood stasis syndrome: a network Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 640-649.
[9]	MENG Xiangran, CAO Xue, SUN Minglin, AI Yanke, HE Liyun, LIU Jia. Effectiveness and safety of Angong Niuhuang pill (安宫牛黄丸) in treatment of acute stroke: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 650-660.
[10]	LUO Xin, XIE Jing, HUANG Li, GAN Wenfan, CHEN Ming. Efficacy and safety of activating blood circulation and removing blood stasis of Traditional Chinese Medicine for managing renal fibrosis in patients with chronic kidney disease: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 429-440.
[11]	GUO Wen, LI Xuanlin, ZHAO Hulei, LEI Siyuan, XIE Yang, LI Jiansheng. Effectiveness of Chinese herbal medicine combined with conventional medicine on acute exacerbation of chronic obstructive pulmonary disease: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 212-220.
[12]	ZHANG Junli, HE Ying, ZHANG Xia, FU Hongfang, HU Xiaoyu. Fuzheng Huayu preparation (扶正化瘀胶囊/片) combined with tenofovir disoproxil fumarate on hepatitis B: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 221-230.
[13]	HUANG Zhaohan, FANG Yuan, WANG Xiaolu, HAN Yue, YU Qi, WANG Tong. Effectiveness of acupuncture-related therapies on schizophrenia: a Bayesian network Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 239-251.
[14]	WANG Yide, GAO Zhen. Yinyanghuo (Herba Epimedii Brevicornus) and its components for chronic obstructive pulmonary disease: preclinical evidence and possible mechanisms [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 386-396.
[15]	YOU Jianyu, LI Haiyan, XIE Dingyi, CHEN Mingren, CHEN Rixin. Efficacy of acupuncture therapy for post-stroke fatigue: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 27-33.

Home

Online First

Author Center

Reviewer Center

Issues

Announcement

About Us